Bevacizumab Plus Paclitaxel Optimization Study with Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer (BOOSTER). This evidence concerns the gene ESR1 and breast cancer.